Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Immune globulin (Primary) ; Hyaluronidase
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Shire
- 07 Sep 2018 Planned End Date changed from 1 Dec 2021 to 30 Sep 2024.
- 07 Sep 2018 Planned primary completion date changed from 1 Dec 2021 to 30 Sep 2024.
- 21 Nov 2016 Status changed from not yet recruiting to recruiting.